Evidence map›Paper›PMID 32867706›Full record

SynthesisBMC infectious diseases2020

Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis.

Yewei Xie, Zaisheng Wang, Huipeng Liao, Gifty Marley, Dan Wu, Weiming Tang

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04625972 (A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies), which is not on this map. Cited by 75 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 6 pooled it
3.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04625972 phase3completednot on this map

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19

TypeinterventionalSponsorAstraZenecaRan2020 to 2022Enrolled1,131ConditionsCOVID-19ArmsAZD7442, Placebo
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 6 syntheses or guidelines pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.Journal of the American College of Cardiology · 2023
    Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Article
  18. Article
  19. Observational
  20. COVID-19 in one region of New Zealand: a descriptive epidemiological study.Australian and New Zealand journal of public health · 2022
    Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Yewei XieDermatology Hospital of Southern Medical University, Guangzhou, China.
Zaisheng WangDermatology Hospital of Southern Medical University, Guangzhou, China.
Huipeng LiaoDermatology Hospital of Southern Medical University, Guangzhou, China.
Gifty MarleyDermatology Hospital of Southern Medical University, Guangzhou, China.
Dan WuDermatology Hospital of Southern Medical University, Guangzhou, China.
Weiming TangDermatology Hospital of Southern Medical University, Guangzhou, China. weimingtangscience@gmail.com.ORCID http://orcid.org/0000-0002-9026-707X
Southern Medical University · CNGuangzhou University · CNLondon School of Hygiene & Tropical Medicine · GB

Funding

Enhancing Partner Services among Men Who Have Sex with Men Living With HIV: A Pilot Randomized Controlled TrialR34MH119963 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TANG, WEIMING, TUCKER, JOSEPH DAVID · 2019 to 2021
$568k
NIMH NIH HHS R34 MH119963NIMH NIH HHS R34MH119963
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has affected the world deeply, with more than 14,000,000 people infected and nearly 600,000 deaths. This review aimed to summarize the epidemiologic traits, clinical spectrum, CT results and laboratory findings of the COVID-19 pandemic.

methodsWe scoped for relevant literatures published during 1st December 2019 to 16th July 2020 based on three databases using English and Chinese languages. We reviewed and analyzed the relevant outcomes.

resultsThe COVID-19 pandemic was found to have a higher transmission rate compared to SARS and MERS and involved 4 stages of evolution. The basic reproduction number (R

conclusionsWe provided a bird's-eye view of the COVID-19 during the current pandemic, which will help better understanding the key traits of the disease. The findings could be used for disease's future research, control and prevention.

Indexed as

PandemicsAgedAge FactorsBetacoronavirusComorbidityCoronavirus InfectionsCoughCOVID-19DemographyDisease ProgressionDyspneaFatigueFemaleFeverHumansLaboratoriesClinical spectrumCOVID-19EpidemiologyLaboratory findingsNature history

Identifiers

PMID32867706
PMCPMC7457225
OpenAlexW3081988469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.